NIFTY 50

Wockhardt drug gets QIDP status from US FDA, Habil Khorakiwala says will take 3-4 years to market

Updated : April 20, 2020 12:56 PM IST

Pharmaceutical major Wockhardt’s antibiotic drug, WCK 6777 has got the qualified infectious disease product (QIDP) designation by the US FDA.

Speaking to CNBC-TV18, Habil Khorakiwala, Founding Chairman and group CEO of Wockhardt said that phase one of clinical trials is about to start. He expects WCK 6777 to take at least 3-4 years before the company is ready to market it.

WCK 6777 is a drug for stomach infections and UTIs, Khorakiwala said that a major advantage of this drug is that it is a once a day treatment and is given via intravenous injection in a hospital.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you